24.19
-0.65 (-2.62%)
| Previous Close | 24.84 |
| Open | 24.82 |
| Volume | 194,891 |
| Avg. Volume (3M) | 480,490 |
| Market Cap | 1,304,069,120 |
| Price / Sales | 367.28 |
| Price / Book | 2.45 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -5,656.01% |
| Diluted EPS (TTM) | -1.67 |
| Quarterly Revenue Growth (YOY) | -11.60% |
| Total Debt/Equity (MRQ) | 0.38% |
| Current Ratio (MRQ) | 47.43 |
| Operating Cash Flow (TTM) | -82.78 M |
| Levered Free Cash Flow (TTM) | -70.18 M |
| Return on Assets (TTM) | -16.91% |
| Return on Equity (TTM) | -28.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Upstream Bio, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 14.84% |
| % Held by Institutions | 89.32% |
| 52 Weeks Range | ||
| Median | 47.00 (94.30%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 14 Oct 2025 | 47.00 (94.30%) | Buy | 19.98 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |